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AbstrACt
Objectives We previously identified that general 
practitioners (GPs) in French-speaking regions of 
Europe had a variable uptake of common preventive 
recommendations. In this study, we describe GPs’ reports 
of how they put different preventive recommendations into 
practice.
Design, setting and participants Cross-sectional 
study conducted in 2015 in Switzerland and France. 
3400 randomly selected GPs were asked to complete 
a postal (n=1100) or online (n=2300) questionnaire. 
GPs who exclusively practiced complementary and 
alternative medicine were not eligible for the study. 764 
GPs (response rate: postal 47%, online 11%) returned 
the questionnaire (428 in Switzerland and 336 in 
France).
Main outcome measures We investigated how the 
GPs performed five preventive practices (screening for 
dyslipidaemia, colorectal and prostate cancer, identification 
of hazardous alcohol consumption and brief intervention), 
examining which age group they selected, the screening 
frequency, the test they used, whether they favoured 
shared decision for prostate cancer screening and their 
definition of hazardous alcohol use.
results A large variability was observed in the way 
in which GPs provide these practices. 41% reported 
screening yearly for cholesterol, starting and stopping 
at variable ages. 82% did not use any test to identify 
hazardous drinking. The most common responses for 
defining hazardous drinking were, for men, ≥21 drinks/
week (24%) and ≥4 drinks/occasion for binge drinking 
(20%), and for women, ≥14 drinks/week (28%) and 
≥3 drinks/occasion (21%). Screening for colorectal cancer, 
mainly with colonoscopy in Switzerland (86%) and stool-
based tests in France (93%), was provided every 10 
years in Switzerland (65%) and 2 years in France (91%) 
to patients between 50 years (87%) and 75 years (67%). 
Prostate cancer screening, usually with shared decision 
(82%), was provided yearly (62%) to patients between 50 
years (74%) and 75–80 years (32%–34%).
Conclusions The large diversity in the way these 
practices are provided needs to be addressed, as it 
could be related to some misunderstandingof the current 
guidelines, to barriers for guideline uptake or, more 
likely, to the absence of agreement between the various 
recommendations.
IntrODuCtIOn
Preventive healthcare practices can be effec-
tive strategies to reduce the burden of chronic 
diseases such as cancer or heart diseases.1–4 
Because chronic diseases are a major cause of 
morbidity and mortality worldwide, preven-
tive healthcare practices have the potential 
to lower medical costs.3 A large number of 
chronic diseases is associated with identified 
and modifiable risk factors.5 6 Therefore, 
despite remaining controversies regarding 
the relevance of some preventive recom-
mendations,7–9 prevention has become an 
essential component of general practitioners’ 
(GPs) tasks.
There has been increasing emphasis on 
the development of evidence-based preven-
tive care guidelines in the last decades, 
such as the US Preventive Services Task 
Force recommendations and the Canadian 
Task Force on Preventive Health Care.10 11 
These North American guidelines are often 
used by GPs in Europe, in combination 
with country-specific recommendations. 
For example, a national programme 
named EviPrev was recently launched in 
strengths and limitations of this study
 ► We previously identified that general practitioners 
(GPs) in French-speaking regions in Europe 
had a variable uptake of common preventive 
recommendations but, to our knowledge, no studies 
assessed how GPs perform preventive activities in 
these countries.
 ► All the answers were self-reported, which could lead 
to social desirability biases.
 ► The recruitment of GPs was restricted to four French-
speaking regions (two in Western Switzerland and 
two in France); this relatively restricted sample may 
not be representative of all GPs practicing either in 
Europe or in French-speaking continental Europe.
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Switzerland to develop local guidelines, taking into 
account the Swiss context.12 These recommendations 
have only recently started to be implemented in clin-
ical practice, and a majority of Swiss GPs do not know 
them in detail. In France, preventive guidelines were 
mostly developed and classified by diseases. There are 
currently no global preventive care recommendations 
in this country.5 Some preventive care recommenda-
tions are available, but they are scattered across various 
disease-specific guidelines published by a variety of 
academic associations.5
Unfortunately, many of these guidelines offer 
contradictory advice. As there is no consensus, it is 
difficult for GPs to determine how to deliver preven-
tive care in their consultations.5 The methodology 
and choice of grading systems to develop these 
guidelines vary, as well as the choice of the clinical 
categories and the target populations, which further 
complicates the delivery of preventive care.5 In 
such a context, it may be difficult for GPs to have a 
precise, global picture of the preventive care they are 
expected to deliver.
Some studies addressed the variation in and the 
barriers to guideline adherence.13–17 Among a wide 
spectrum of barriers, the lack of awareness or famil-
iarity with the guidelines is often cited by GPs.16 17 This 
factor may, at least in part, be explained by the lack 
of agreement between the recommendations and, in 
many countries, by the absence of national programme 
dedicated to implementation of prevention guidelines 
in general practices. Moreover, GPs seem to perceive 
some recommendations as not being applicable in 
daily practice, either because their patient popula-
tions are highly heterogeneous or because they are 
‘complex’.16 17 These barriers could probably in part 
be overcome if GPs were more often involved in the 
development process of these guidelines, which is 
often not the case.16
The lack of awareness of the local guidelines and the 
discrepancies between the various available guidelines 
could alter the way the different recommendations 
are carried out. Therefore, in order to add new data 
coming from French-speaking Continental Europe to 
the literature assessing how GPs perform preventive 
activities, we found that it is important to explore how 
they are provided regarding both the target popula-
tions and the screening tests used by documenting 
self-reported preventive care practices in four French-
speaking regions. We also aimed to investigate whether 
these findings were associated with some GP character-
istics, in particular their country of practice (Switzer-
land and France). The two countries differ in several 
aspects related to medical practice, as for example 
methods of reimbursement of medical costs (benefits 
are based on preset rates in France and fee-for-service 
in Switzerland) and in preventive recommendations 
(no unified preventive recommendations’ document 
in France).5
MethODs
study site, study population and sample size justification
This study was part of a larger project designed to assess 
French-speaking GPs’ preventive care practices. This was 
a cross-sectional autoadministered questionnaire-based 
study that took place in 2015 in four French-speaking 
regions in two countries (Switzerland: cantons of Geneva 
and Vaud; and France: Alsace and Pays de la Loire). Alsace 
and Pays de Loire are approximately in the mid-French 
level in relation to rurality, medical density and GPs’ 
density.18 19 Vaud and Geneva are more urban than other 
cantons in Switzerland and their total medical density 
and GPs’ density exceed average Swiss values.20–22
We randomly selected 1000 community-based GPs prac-
ticing in Switzerland (600 in the canton of Geneva and 
400 in the canton of Vaud) and 2400 in France (1200 in 
Alsace and 1200 in Pays de la Loire) from the regional 
professional organisation lists and invited them to partici-
pate in the study by email (300 in Switzerland and 2000 in 
France) or by post (700 in Switzerland and 400 in France). 
We sent reminder messages (maximum twice per GP) if 
they had not responded to the first invitation. We used 
simple randomisation based on computer-generated 
random numbers to allocate them to the postal or the 
web-based group. The postal letters included a stamped 
return envelope. GPs who exclusively practiced comple-
mentary and alternative medicine were not eligible 
to take part in our project. No other exclusion criteria 
were applied to the study. We described the recruitment 
process in detail in a previous paper.23
sample size estimation
We estimated the minimal required sample size of 600 to 
be able to provide a 95% CI no wider than ±4% for every 
estimate of prevalence of preventive activities, with an 
expected prevalence of about 50%.24 25 As we assumed a 
participation rate of 25%, we had to contact 2400 GPs. We 
decided to increase the sample size to 3400 to take into 
account the presence of incomplete questionnaires.26 27
Data collection
A research assistant located in Geneva contacted the 
randomly selected GPs practicing in Switzerland (in 
France, this task was carried out by the local GPs’ repre-
sentative structure: Union Régionale des Professionnels de 
Santé Alsace and Pays de la Loire) and informed them about 
the aim of the study and the practical procedures to be 
followed to complete the anonymous questionnaire.
The questionnaire (see online supplementary file 1) 
included sociodemographic questions (age, gender, 
number of working days per week and number of working 
years in the practice), and questions about the frequency 
of use of 12 preventive practices (blood pressure, weight 
and height measurements, screening for dyslipidaemia, 
hazardous drinking (and advice to decrease drinking for 
hazardous drinkers), tobacco smoking (and advice to stop 
smoking for smokers), colorectal and prostate cancer; 
and influenza immunisation for patients >65 years and 
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at-risk patients <65 years), using a 5-point Likert scale 
ranging from ‘never performed’ to ‘always performed’.
Ten of these preventive practices were selected because 
they had been part of previous studies evaluating the 
quality of preventive care in Switzerland.28 We added two 
additional practices: cholesterol measurement, because it 
is a highly recommended intervention in preventive care, 
and screening for prostate cancer, because several Swiss 
and French medical agencies recently recommended 
against systematic screening.5 29–31 We did not include 
diabetes screening in our project, because it is only 
recommended when other cardiovascular risk factors 
are present.32 33 We did not include screening for breast 
and cervical cancer either because, in Switzerland, they 
are often carried out by gynaecologists, in particular in 
mostly urban cantons such as Geneva and Vaud.
We restricted the data presented here to five preven-
tive care practices for which we asked additional ques-
tions about how GPs were providing them (four practices 
regarding screening: dyslipidaemia, hazardous drinking, 
colorectal and prostate cancer; and one regarding 
counselling: advice to decrease drinking for hazardous 
drinkers). These five practices were selected because they 
illustrate the three major topics leading to high morbidity 
and mortality in most high-income countries (cardiovas-
cular diseases, cancers and addictions) and because they 
can be applied in a variety of ways.34 35 For the screening 
of dyslipidaemia, colorectal and prostate cancers, we 
asked GPs to specify screening starting and ending ages 
and screening frequency. We also asked which diag-
nostic test they were generally using for the screening 
of dyslipidaemia (full lipid profile or total cholesterol) 
and colorectal cancer (colonoscopy or stool-based tests 
(guaiac faecal occult blood test or faecal immunochem-
ical test (FIT)) and whether they usually screened for 
prostate cancer in the context of a shared and informed 
decision process. Finally, we asked them whether they 
used a validated questionnaire to screen for hazardous 
drinking (and if yes, which one) and which definitions of 
hazardous, including binge drinkers, they were generally 
using.
Seven GPs pretested the questionnaire so as to ensure 
that it was understandable and easy to complete. All 
collected data remained confidential throughout the 
study. We assumed that a tacit consent was given when 
a GP returned the completed questionnaire. We did 
not collect any data regarding GPs who had refused to 
participate in the study. In Switzerland, informed consent 
waiving was granted by the Research Ethics Committee 
of Geneva (under Swiss law informed consent is required 
when collecting personal health data, not when exploring 
practices), whereas in France, the research protocol was 
approved by the Groupe nantais d’éthique en santé (ref: 
2015-09-06).
statistical analyses
We computed the proportion of GPs delivering each of 
the five preventive practices, defined as the proportion of 
GPs scoring 4 or 5/5 on the Likert scale, with estimated 
95% CIs. Proportions were also split by country, gender 
and age group. Multivariate analysis adjusting for country, 
gender and class of age were also performed. Differences 
of proportion were tested with χ2 tests. For quantitative 
values (eg, age, frequency and number of glasses) t-test 
were used. Statistical significance was set at a two-sided 
p value of ≤0.05. All the analyses were carried out with 
TIBCO Spotfire S+ 8.1 for Windows (TIBCO Software, 
Palo Alto, California, USA) or R V.3.2.2 (R Foundation 
for Statistical Computing, Vienna, Austria).
results
Among the 3400 GPs who were selected at random 
(1000 in Switzerland and 2400 in France), 764 (response 
rate: 47% in postal group and 11% in online group) 
responded to the questionnaire (428 in Switzerland and 
336 in France). Table 1 presents their main sociodemo-
graphic characteristics, overall and by country of practice. 
The GPs’ distribution by gender was relatively similar in 
the two countries (men: 59% in Switzerland vs 58% in 
France), as well as the number of half-days worked per 
week (8.5 vs 8.7). Some differences could be observed 
regarding the age distribution (>64 years: 13% in Swit-
zerland vs 6% in France; <35 years: 1% in Switzerland vs 
8% in France) and the number of working years in the 
current practice (20 in France vs 17 in Switzerland). Our 
sample appears to be similar in age and gender to all GPs 
practicing in Switzerland (professional organisation of 
Swiss physicians, 2016: median age 54 years (vs 54 years in 
our study), men 59% (vs 59% in our study)) and France 
(Pays de Loire, 2013: median age 51 years (vs 48 years in 
our study), men 57% (vs 53% in our study)).22 36
Tables 2 and 3 show the self-reported preventive care 
practices in the two countries. A large variability was 
observed in the way in which GPs applied these preven-
tive recommendations. In general, screening for dyslipi-
daemia (93% with full lipid profile test) was provided yearly 
to patients who were 40–80 years old. The vast majority of 
GPs did not use any test to screen for hazardous drinking 
(77% in Switzerland and 91% in France), but when they 
did use one, the CAGE was most frequently chosen in both 
countries. For the majority of GPs, hazardous drinking 
was defined as the consumption of ≥21 drinks/week for 
men and 14 drinks/week for women, and as ≥4 drinks/
occasion for men and three drinks/occasion for women, 
for both countries. Screening for colorectal cancer, 
mainly with colonoscopy in Switzerland (86%) and FIT in 
France (93%), was provided every 10 years in Switzerland 
and every 2 years in France to patients who were 50–75 
years old. Finally, screening for prostate cancer, usually 
in the context of a shared decision (82%), was provided 
yearly to patients who were 50 to 75-80 years old.
 Online supplementary file 2 and supplementary file 
3 show the self-reported GPs’ preventive care practices 
by GP gender and age group (for online supplemen-
tary file 2 screening for dyslipidaemia and hazardous 
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drinking and online supplementary file 3 for colorectal 
and prostate cancer screening). There are only very few 
differences between the groups regarding the character-
istics of the preventive care practices. Colorectal cancer 
screening was proposed (with colonoscopy) every 10 
years by a majority of GPs <55 years (70%), and prostate 
cancer yearly by a majority of female GPs (69%), whereas 
higher dispersions (ie, higher variability) were observed 
among older GPs for colorectal cancer and male GPs for 
prostate cancer.
DIsCussIOn
summary
We identified a large variability in the way in which 
French-speaking GPs apply preventive care recommen-
dations. The association between GPs’ gender, age and 
country of practice and the way they apply preventive 
recommendation is generally small, except for screening 
for colorectal cancer (colonoscopy in Switzerland vs FIT 
in France).
Comparison with existing literature
The results of this study showed a high diversity in 
the way preventive care was provided by GPs, which 
frequently was not in accordance with local guidelines 
(see online supplementary file 4 for Swiss12 29 32 33 37–39 
and French recommendations6 30 31 40–45 on how GPs are 
expected to deliver these five preventive care practices). 
Screening for colorectal cancer is however the archetypal 
example of a screening carried out according to the usual 
recommendations. Indeed, a large majority of GPs screen 
the recommended target population (patients between 
50 and 75 years old), using common screening tests (colo-
noscopy or stool-based tests in Switzerland and mainly 
stool-based tests in France), with the recommended 
screening frequency (every 10 years for colonoscopy in 
Switzerland and every 2 years for FIT in France). Note 
that stool-based tests are provided by less than one-fifth 
of Swiss GPs, though it is an alternative recommended 
screening test for colorectal cancer in this country. This 
finding is in accordance with a recent study showing a 
growth in colorectal cancer screening due to greater 
use of endoscopy (increase of colonoscopy utilisation 
from 8% to 15% and decrease of stool-based tests utili-
sation from 13% to 10% between 2007 and 2012).46 FIT 
(and not colonoscopy) is the most frequently used test in 
France as part of the national screening programme for 
colorectal cancer in this country. However, it should be 
borne in mind that FIT is the recommended screening 
test for general populations without specific risk factors. 
Colonoscopy, however, is recommended for higher risk 
patients such as, for example, patients with a family 
history of colorectal cancer. There is currently no national 
screening programme in Switzerland.
Different results with much higher heterogeneity are 
observed for screening for dyslipidaemia and prostate 
cancer and counselling for hazardous alcohol consump-
tion. Only one-third of Swiss and French GPs screen for 
dyslipidaemia as from the age of 40 years (the recom-
mended starting age in the two countries), and only 8% 
of Swiss GPs and 20% of French GPs, respectively, follow 
the recommended 5-year screening frequency.
Similarly, though the majority of GPs screen prostate 
cancer from 50 years (the recommended starting age 
for Switzerland), less than one-third of Swiss GPs stops 
screening at the recommended age of 75 years (almost 
half of Swiss GPs stops screening at 70 or 80 years).
For the majority of GPs, hazardous drinking was defined 
as the consumption of ≥21 drinks/week for men and 
14 drinks/week for women, and as ≥4 drinks/occasion 
Table 1 General practitioners’ characteristics in the two countries (n=764)
Characteristics Switzerland (n=428) France (n=336) Total (n=764)
n* (%) n* (%) p Value† n* (%)
Gender
  Male 240 (59.1) 188 (58.0) 0.83 428 (55.6)
  Female 166 (40.9) 136 (42.0) 302 (44.4)
Age group (years)
  <35 2 (0.5) 27 (8.2) <0.001 29 (3.9)
  35–44 94 (23.1) 63 (19.0) 157 (21.3)
  45–54 112 (27.5) 86 (26.0) 198 (26.8)
  55–64 148 (36.4) 134 (40.5) 282 (38.2)
  >64 51 (12.5) 21 (6.3) 72 (9.8)
Mean±SD Mean±SD Mean±SD
Mean number of half-days worked per week 8.5±2.5 8.7±2.0 0.31 8.6±2.3
Number of working years in the current practice 16.7±10.5 19.6±11.5 <0.001 18.0±11.1
*Numbers do not add up to 428, 336 and 764 because of missing values.
†Comparisons of proportions were made with χ2 tests; comparisons of continuous values were made with Student’s t-test.
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Table 2 Self-reported preventive care practices of general practitioners in the two countries: screening for dyslipidaemia and 
hazardous drinking
Characteristics
Switzerland 
(n=428)
France 
(n=336)
Total 
(n=764)
% 95% CI % 95% CI p Value* % 95% CI
Screening for dyslipidaemia
  Starting age 0.005
   30 years 15.8 12.0 to 19.7 18.7 13.9 to 23.6 17.1 14.0 to 20.1
   40 years 32.0 27.0 to 36.9 35.5 29.5 to 41.4 33.4 29.6 to 37.2
   45 years 8.2 5.3 to 11.1 7.2 4.0 to 10.4 7.8 5.6 to 9.9
   50 years 15.2 11.4 to 19.1 11.6 7.6 to 15.5 13.7 10.9 to 16.5
   Other 28.7 23.9 to 33.5 27.1 21.6 to 32.6 28.0 24.4 to 31.7
  Ending age 0.82
   70 years 12.9 9.3 to 16.5 12.7 8.6 to 16.9 12.8 10.1 to 15.5
   75 years 20.5 16.2 to 24.8 16.3 11.8 to 20.9 18.8 15.6 to 21.9
   80 years 37.2 32.1 to 42.4 39.8 33.8 to 45.9 38.3 34.4 to 42.3
   100 years 6.7 4.1 to 9.4 7.2 4.0 to 10.4 6.9 4.9 to 9.0
   Other 22.6 18.1 to 27.0 23.9 18.6 to 29.2 23.1 19.7 to 26.5
  Screening frequency <0.001
   Yearly 46.9 41.6 to 53.2 32.3 26.5 to 38.1 40.7 36.8 to 44.7
   Every 2 years 27.0 22.3 to 31.7 26.3 20.8 to 31.7 26.7 23.1 to 30.3
   Every 3 years 9.4 6.3 to 12.5 15.5 11.1 to 20.0 12.0 9.4 to 14.6
   Every 5 years 7.6 4.8 to 10.4 19.5 14.6 to 24.4 12.7 10.0 to 15.3
   Other 9.1 6.0 to 12.1 6.4 3.4 to 9.4 7.9 5.8 to 10.1
  Test used 0.96
   Total cholesterol 3.8 1.8 to 5.8 4.4 1.9 to 6.9 4.1 2.5 to 5.6
   Full lipid profile 91.5 88.5 to 94.5 94.4 91.6 to 97.3 92.7 90.6 to 94.8
Screening for hazardous drinking
  Test used <0.001
   No 77.2 72.4 to 81.9 91.4 87.2 to 95.5 82.4 79.0 to 85.8
   Yes 20.8 16.2 to 25.4 8.1 4.0 to 12.1 16.1 12.8 to 19.4
    AUDIT  24.2 13.5 to 34.9 28.6 4.9 to 52.2 25.0 15.3 to 34.7
    CAGE 77.4 67.0 to 87.8 57.1 31.2 to 83.1 73.7 63.8 to 83.6
    MAST 6.5 0.3 to 12.6 21.4 0.0 to 42.9 9.2 2.7 to 15.7
Advice to decrease drinking for hazardous drinkers
  Definition of male hazardous drinkers 0.05
   ≥14 drinks/week 12.0 8.4 to 15.6 7.4 4.2 to 10.6 9.9 7.4 to 12.4
   ≥15 drinks/week 6.8 4.0 to 9.6 7.4 4.2 to 10.6 7.1 5.0 to 9.2
   ≥20 drinks/week 14.2 10.3 to 18.1 16.7 12.2 to 21.3 15.4 12.4 to 18.3
   ≥21 drinks/week 22.0 17.4 to 26.6 25.3 20.0 to 30.6 23.5 20.0 to 27.0
   Other 45.0 39.4 to 50.5 43.2 37.1 to 49.2 44.2 40.1 to 48.3
  Definition of female hazardous drinkers 0.08
   ≥7 drinks/week 12.9 9.2 to 16.7 6.2 3.3 to 9.2 9.9 7.4 to 12.4
   ≥10 drinks/week 9.1 5.9 to 12.3 11.7 7.7 to 15.6 10.2 7.7 to 12.7
   ≥14 drinks/week 26.5 21.6 to 31.5 30.0 24.4 to 35.6 28.1 24.4 to 31.8
   ≥15 drinks/week 10.4 7.0 to 13.8 13.6 9.4 to 17.8 11.8 9.2 to 14.5
   Other 41.1 35.6 to 46.6 38.5 32.6 to 44.5 39.9 35.9 to 44.0
  Definition of male binge drinkers 0.09
   ≥3 drinks/occasion 11.3 7.8 to 14.9 14.0 9.8 to 18.3 12.5 9.8 to 15.3
   ≥4 drinks/occasion 15.5 11.5 to 19.6 24.5 19.3 to 29.8 19.6 16.3 to 22.9
Continued
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for men and three drinks/occasion for women, for 
both countries. Note that, in recent years, several coun-
tries have revised their guidelines regarding hazardous 
alcohol drinking, including France.47 The French expert 
group recommends in its recent publication (May 2017) 
that alcohol consumers take no more than 10 standard 
drinks per week and no more than two standard drinks 
per day for men and women.47 These thresholds have 
been chosen, because they represent an absolute lifetime 
risk of alcohol-related mortality for the French popula-
tion between 1% and 1 per 1000.
Some of the reasons for not performing prevention 
practices according to recommendations (such as lack 
of time and method of reimbursement for medical care) 
can vary between countries, which could partly explain 
the country differences in our study. In France, the 
healthcare system is separated into three sectors and GPs 
have to choose in which sector they wish to work. The 
government regulates rates for medical consultations 
within sector 1 (ie, preset fixed fees per consultation). In 
Sector 2, higher fees are allowed within reason, and in 
sector 3, there are no fee limits. A large majority of GPs 
are in sector 1. By contrast, the Swiss ambulatory health-
care system is based on fee-for-service payments that are 
related to the consultation time.48
Major changes in GPs’ profile and activities are 
observed in many Western countries (including France 
and Switzerland). Nowadays, GPs are older, more often 
female and they more often work in group practices.48 In 
Switzerland, whereas the number of face-to-face consulta-
tions is lower, the median time of consultation tends to be 
longer (20 min vs 15 min in France).48–50 When compared 
with other European countries, the consultation time is 
particularly high in Switzerland.49
The large diversity in the way screening for dyslipi-
daemia and prostate cancer are provided could be related 
to three interrelated factors: lack of knowledge of the 
current guidelines, barriers to guideline adherence and 
lack of agreement between the various available recom-
mendations.5 16 17
The relative lack of knowledge of the guidelines could 
in part be attributed to the rapid evolution of scientific 
knowledge, which in turn requires frequent modifications 
in the guidelines. However, this factor (lack of awareness) 
is probably also explained by lack of agreement between 
the various recommendations, which is corroborated 
by our finding that a large majority of GPs screen for 
colorectal cancer appropriately, that is, in accordance 
with the recommendations; indeed, the guidelines used 
for screening colorectal cancer show a relatively high 
level of agreement compared with those proposed in rela-
tion to screening for dyslipidaemia and prostate cancer.
The variability of the current guidelines is probably not 
linked to variations in access to scientific knowledge, because 
all medical agencies, researchers and experts are expected 
to develop their recommendations on the same evidence-
based data.5 Differences in settings, local epidemiological, 
socioeconomic and cultural contexts, perceptions of health-
care priorities and health delivery systems, may all explain 
some of the discrepancies between the guidelines.5
Among a wide spectrum of barriers to guideline adher-
ence, such as lack of motivation, patients’ preferences, 
time and organisational constraints, GPs may perceive 
some recommendations as not being applicable in daily 
practice.16 17 These barriers could probably be in part over-
come if GPs were more often involved in the development 
of these guidelines. More frequent appraisal and adapta-
tion of guidelines using an assessment instrument such 
as Appraisal of Guidelines for Research and Evaluation is 
also an essential way of favouring higher uptake by GPs.51 
Yet, the lack of awareness or familiarity with the guidelines 
is often mentioned by GPs as a barrier to guideline adher-
ence, which again may be related to the diversity of current 
guidelines and to the absence of national programmes to 
implement prevention guidelines in general practices in 
French-speaking countries.16 17
Characteristics
Switzerland 
(n=428)
France 
(n=336)
Total 
(n=764)
% 95% CI % 95% CI p Value* % 95% CI
   ≥5 drinks/occasion 13.9 10.1 to 17.8 15.6 11.1 to 20.0 14.7 11.7 to 17.6
   ≥6 drinks/occasion 6.2 3.5 to 8.8 8.2 4.8 to 11.5 7.1 5.0 to 9.2
   Other 53.1 47.5 to 58.6 37.7 31.8 to 43.7 46.1 42.0 to 50.2
  Definition of female binge drinkers 0.22
   ≥2 drinks/occasion 10.4 7.0 to 13.8 15.6 11.1 to 20.0 12.7 10.0 to 15.5
   ≥3 drinks/occasion 19.4 15.0 to 23.8 23.3 18.2 to 28.5 21.2 17.8 to 24.6
   ≥4 drinks/occasion 13.9 10.1 to 17.8 15.6 11.1 to 20.0 14.7 11.7 to 17.6
   ≥5 drinks/occasion 7.1 4.3 to 10.0 10.5 6.8 to 14.3 8.7 6.3 to 11.0
   Other 49.2 43.6 to 54.8 35.0 29.2 to 40.9 42.8 38.7 to 46.8
*Comparisons of proportions were made with χ2 tests.
AUDIT, Alcohol Use Disorders Identification Test; CAGE, acronym of its four questions (Cut down, Annoyed, Guilty, Eye-opener); MAST, 
Michigan Alcoholism Screening Test.
Table 2 Continued 
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Over the last decades, attention mainly focused on 
underuse of various preventive practices, such as screening 
for dyslipidaemia and cancers.52 However, overuse can 
also be problematic because of unnecessary costs as well 
as patient burden (psychological and other risks) from 
overdiagnosis. We showed that a certain number of GPs 
overuse preventive practices (eg, overall, 17% of GPs 
report starting screening for dyslipidaemia at 30 years, 
whereas 40 years is the recommended starting age in the 
two countries). Overutilisation of preventive practices has 
Table 3 Self-reported preventive care practices of general practitioners in the two countries: screening for colorectal and 
prostate cancer
Characteristics
Switzerland 
(n=428)
France 
(n=336)
Total 
(n=764)
% 95% CI % 95% CI p Value* % 95% CI
Screening for colorectal cancer
  Starting age <0.001
   40 years 3.4 1.5 to 5.3 7.3 4.3 to 10.3 5.2 3.4 to 6.9
   50 years 87.4 84.0 to 90.0 86.5 82.6 to 90.4 87.0 84.4 to 89.6
   55 years 3.4 1.5 to 5.3 0.7 0.0 to 1.6 2.2 1.1 to 3.3
   Other 5.7 3.3 to 8.1 5.5 2.9 to 8.2 5.6 3.8 to 7.4
  Ending age <0.001
   70 years 17.1 13.2 to 21.1 9.0 5.7 to 12.3 13.5 10.8 to 16.1
   74 years 0.3 0.0 to 0.8 9.7 6.3 to 13.1 4.5 2.9 to 6.2
   75 years 63.7 58.7 to 68.8 70.6 65.3 to 75.8 66.8 63.2 to 70.5
   80 years 35.4 30.4 to 40.4 15.2 11.1 to 19.4 26.3 22.9 to 29.7
   Other 18.9 14.8 to 23.0 10.7 7.2 to 14.3 15.2 12.4 to 18.0
  Test used <0.001
   Colonoscopy 86.3 82.7 to 89.9 5.2 2.6 to 7.7 49.6 45.7 to 53.5
   FOBT or FIT 12.0 8.6 to 15.4 93.1 90.2 to 96.0 48.7 44.8 to 52.5
  Screening frequency if colonoscopy <0.001
   5 years 18.5 14.2 to 22.9 66.7 42.8 to 90.5 20.8 16.4 to 25.3
   10 years 64.9 59.5 to 70.3 0.0 61.8 56.5 to 67.2
   Other 16.6 12.4 to 20.7 33.3 9.5 to 57.2 17.5 13.2 to 21.5
  Screening frequency if FOBT or FIT 0.70
   Yearly 31.0 17.0 to 44.9 2.2 0.5 to 4.0 6.1 3.4 to 8.8
   2 years 47.6 32.5 to 62.7 91.4 88.1 to 94.8 85.5 81.6 to 89.4
   Other 21.4 15.0 to 33.8 6.3 3.4 to 9.2 8.4 5.3 to 11.4
Screening for prostate cancer
  Starting age 0.11
   45 years 9.7 5.9 to 13.5 8.9 4.8 to 12.9 9.3 6.6 to 12.1
   50 years 70.9 65.1 to 76.7 77.1 71.1 to 83.0 73.7 69.5 to 77.8
   Other 19.4 14.4 to 24.4 14.1 9.1 to 19.0 17.0 13.5 to 20.6
  Ending age 0.25
   70 years 19.4 14.4 to 24.4 7.3 3.6 to 11.0 14.0 10.7 to 17.3
   75 years 31.2 25.3 to 37.1 37.0 30.2 to 43.8 33.8 29.3 to 38.3
   80 years 28.3 22.5 to 34.0 36.5 29.7 to 43.3 31.9 27.5 to 36.3
   Other 21.1 15.9 to 26.3 19.3 13.7 to 24.8 20.3 16.5 to 24.1
  Screening frequency <0.001
   Yearly 52.3 46.0 to 58.7 72.9 66.6 to 79.2 61.5 56.9 to 66.1
   2 years 32.1 26.1 to 38.0 21.9 16.0 to 27.7 27.5 23.3 to 31.7
   Other 15.6 11.0 to 20.2 5.2 2.1 to 8.4 11.0 8.0 to 13.9
  Shared decision 88.2 81.2 to 92.3 75.0 68.9 to 81.1 <0.001 82.3 78.7 to 85.9
*Comparisons of proportions were made with χ2 tests.
FIT, faecal immunochemical test; FOBT, faecal occult blood test.
8 Sebo P, et al. BMJ Open 2017;7:e017958. doi:10.1136/bmjopen-2017-017958
Open Access 
been shown in particular for dyslipidaemia as well as for 
colorectal, breast, cervical and prostate cancer52 53 and 
could be explained in two ways: lack of knowledge of the 
current guidelines and also by the fact that GPs could be 
put under pressure by their patients to perform certain 
practices, even if they are not recommended. Overuse of 
lab tests-based screening (such as screening for dyslipi-
daemia) has also been shown in patients requiring repeat 
blood tests to follow-up various comorbidities and in rela-
tion to treat-to-target lipid lowering strategies.54
Several actions may help to improve the current situ-
ation and overcome the obstacles that have been iden-
tified above (gaps in knowledge, barriers to guideline 
adherence and lack of agreement between guidelines). 
For example, we could mention the development and 
implementation of guidelines specifically dedicated to 
prevention activities, the involvement of GPs in their 
development and in the establishment of a prioritisation 
process, the organisation of nationwide campaigns, the 
use of recall systems and the implementation of a system-
atic performance monitoring.5 6 55 However, we consider 
that these practices should be complemented by harmon-
isation of the current guidelines, at least at a European 
level, to be fully effective. There is often a low level of 
agreement between the various guidelines and high vari-
ability in the choice of methodology and grading system is 
observed in their development. The choice of the clinical 
categories and the target populations could also be prob-
lematic, resulting in a number of difficulties to determine 
to whom and how preventive care should be provided. 
limitations
Several limitations should be kept in mind when consid-
ering the results of this study. First, all the answers were 
self-reported, which could lead to social desirability biases 
(ie, natural tendency to engage in socially desirable 
responding by over-reporting good behaviour and/or 
under-reporting undesirable behaviour).56 Second, the 
recruitment of GPs was restricted to four French-speaking 
regions (two in Western Switzerland and two in France); 
this relatively restricted sample may not be representa-
tive of all GPs practicing either in Europe or in French-
speaking continental Europe. Third, although nearly 
half of those invited to participate by post returned the 
questionnaire, response rates in those who were invited 
to respond online were very low (11%). Therefore, the 
hypothesis of a different profile between responders 
and non-responders cannot be ruled out. However, we 
assumed a total participation rate of 25% in the calcula-
tion of our sample size, and our study sample size was in 
fact higher than the estimated minimal required sample 
size for our study. In addition, our sample appears to be 
representative in terms of age and gender of all GPs prac-
ticing in Switzerland and France (data from Pays de la 
Loire). The fact that response rates were higher for Swiss 
(43%) compared with French GPs (14%) could also intro-
duce a certain degree of selection bias. Fourth, though 
the GPs practicing in Switzerland showed fairly similar 
sociodemographic characteristics to those practicing in 
France, they were some slight differences regarding the 
age distribution and the experience as GP, which might 
have led to additional bias.
Implications for research and practice
In conclusion, the large heterogeneity in the way preven-
tive care is provided need to be addressed, as it could 
be related to some misunderstanding of the current 
guidelines, to barriers to guideline adherence or, more 
likely, to the absence of agreement between the various 
recommendations. Considerable efforts should be made 
to harmonise the current guidelines and implement 
them in primary care offices. This is an essential task to 
improving the quality of preventive care and, in fine, to 
reducing the burden of chronic diseases and medical 
costs.
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